A member of the M23 insurgent group stands guard as Provincial authorities go to the Rodolphe Merieux Laboratory, Nationwide Biomedical Analysis Institute (INRB), the place samples from suspected Ebola instances are examined, as a part of the response to the epidemic in Goma, North Kivu Province of the Democratic Republic of Congo. File
| Picture Credit score: Reuters
Greater than 16,000 doses of the Ervebo vaccine arrived within the Democratic Republic of Congo (DRC) late Friday (August 21, 2026), an AFP journalist noticed, because the nation faces its deadliest Ebola outbreak in historical past.
The DRC’s seventeenth Ebola outbreak, which has killed 1000’s of individuals, was declared on Might 15 however is assumed to have been spreading for a number of weeks prior.
It has hit areas within the north and east the place the presence of the state is weak, well being infrastructure is basically missing and myriad armed teams have roamed for many years.
The World Well being Organisation (WHO) introduced on Thursday (August 20) that the DRC would obtain 70,000 doses of the Ervebo vaccine, produced in Germany.
The vaccine, developed by the pharmaceutical firm Merck, is permitted in opposition to the Zaire pressure of the virus, however not in opposition to the Bundibugyo pressure at the moment circulating within the nation.
WHO consultants nonetheless have no idea whether or not Ervebo protects people in opposition to the Bundibugyo pressure, however early information, notably from animal trials, counsel it might supply some safety.
The Ervebo vaccine “has already been used a number of occasions, and particularly on a really massive scale throughout the 2018-2020 outbreak”, Samuel Roger Kamba, the DRC’s Minister of Well being, instructed the press.
He was talking on the tarmac of Kinshasa airport, the place a batch of 16,250 doses was delivered by aircraft on Friday (August 21).
Of the 70,000 doses made obtainable to the DRC, 20,000 are meant for a scientific trial, and 50,000 for “frontline and well being employees” within the DRC, the WHO defined on Thursday (August 20).
The Ebola outbreak in the DRC has already caused 2,516 deaths amongst 5,290 confirmed instances, based on the most recent information printed by the Congolese authorities.
It “is rising exponentially”, warned Julien Harneis, the UN’s senior Ebola coordinator, on Friday (August 21).
This month, WHO vaccine consultants beneficial a full-scale human trial of Ervebo, the one current permitted Ebola vaccine, to see if it supplied cross-protection in opposition to the Bundibugyo pressure.
Two vaccines particularly concentrating on the Bundibugyo pressure are in scientific trial phases: one is being developed by the U.S.-based group Moderna, which makes use of mRNA know-how, and the opposite by Britain’s College of Oxford.
As well as, an “rVSV Bundibugyo” vaccine, described by the WHO as “essentially the most promising”, is to be developed by Singapore-based Hilleman Laboratories.
Ebola, which is transmitted by means of contact with bodily fluids and causes fever, has killed greater than 15,000 individuals in Africa over the previous 50 years.
Printed – August 22, 2026 09:45 am IST
